S&P 500   4,296.64 (-0.01%)
DOW   34,101.53 (+0.56%)
QQQ   333.52 (+0.14%)
AAPL   173.17 (-0.01%)
MSFT   293.42 (-0.02%)
META   180.33 (-0.31%)
GOOGL   122.00 (-0.07%)
AMZN   145.90 (+1.90%)
TSLA   926.94 (-0.11%)
NVDA   190.29 (-0.02%)
NIO   21.00 (-1.41%)
BABA   93.20 (-1.06%)
AMD   100.73 (-0.28%)
MU   64.33 (-0.57%)
T   18.65 (+1.41%)
CGC   3.85 (+0.79%)
F   16.58 (+1.59%)
GE   81.14 (+1.67%)
DIS   126.45 (+1.76%)
AMC   25.34 (+4.67%)
PYPL   102.73 (+1.20%)
PFE   50.03 (+0.56%)
NFLX   248.38 (-0.29%)
S&P 500   4,296.64 (-0.01%)
DOW   34,101.53 (+0.56%)
QQQ   333.52 (+0.14%)
AAPL   173.17 (-0.01%)
MSFT   293.42 (-0.02%)
META   180.33 (-0.31%)
GOOGL   122.00 (-0.07%)
AMZN   145.90 (+1.90%)
TSLA   926.94 (-0.11%)
NVDA   190.29 (-0.02%)
NIO   21.00 (-1.41%)
BABA   93.20 (-1.06%)
AMD   100.73 (-0.28%)
MU   64.33 (-0.57%)
T   18.65 (+1.41%)
CGC   3.85 (+0.79%)
F   16.58 (+1.59%)
GE   81.14 (+1.67%)
DIS   126.45 (+1.76%)
AMC   25.34 (+4.67%)
PYPL   102.73 (+1.20%)
PFE   50.03 (+0.56%)
NFLX   248.38 (-0.29%)
S&P 500   4,296.64 (-0.01%)
DOW   34,101.53 (+0.56%)
QQQ   333.52 (+0.14%)
AAPL   173.17 (-0.01%)
MSFT   293.42 (-0.02%)
META   180.33 (-0.31%)
GOOGL   122.00 (-0.07%)
AMZN   145.90 (+1.90%)
TSLA   926.94 (-0.11%)
NVDA   190.29 (-0.02%)
NIO   21.00 (-1.41%)
BABA   93.20 (-1.06%)
AMD   100.73 (-0.28%)
MU   64.33 (-0.57%)
T   18.65 (+1.41%)
CGC   3.85 (+0.79%)
F   16.58 (+1.59%)
GE   81.14 (+1.67%)
DIS   126.45 (+1.76%)
AMC   25.34 (+4.67%)
PYPL   102.73 (+1.20%)
PFE   50.03 (+0.56%)
NFLX   248.38 (-0.29%)
S&P 500   4,296.64 (-0.01%)
DOW   34,101.53 (+0.56%)
QQQ   333.52 (+0.14%)
AAPL   173.17 (-0.01%)
MSFT   293.42 (-0.02%)
META   180.33 (-0.31%)
GOOGL   122.00 (-0.07%)
AMZN   145.90 (+1.90%)
TSLA   926.94 (-0.11%)
NVDA   190.29 (-0.02%)
NIO   21.00 (-1.41%)
BABA   93.20 (-1.06%)
AMD   100.73 (-0.28%)
MU   64.33 (-0.57%)
T   18.65 (+1.41%)
CGC   3.85 (+0.79%)
F   16.58 (+1.59%)
GE   81.14 (+1.67%)
DIS   126.45 (+1.76%)
AMC   25.34 (+4.67%)
PYPL   102.73 (+1.20%)
PFE   50.03 (+0.56%)
NFLX   248.38 (-0.29%)
NASDAQ:PRQR

ProQR Therapeutics - PRQR Stock Forecast, Price & News

$0.88
-0.01 (-1.57%)
(As of 08/16/2022 02:25 PM ET)
Add
Compare
Today's Range
$0.86
▼
$0.89
50-Day Range
$0.68
▼
$0.89
52-Week Range
$0.53
▼
$9.09
Volume
5,461 shs
Average Volume
451,041 shs
Market Capitalization
$62.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
468.2% Upside
$5.00 Price Target
Short Interest
Healthy
0.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of ProQR Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.72) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

212th out of 1,124 stocks

Pharmaceutical Preparations Industry

95th out of 555 stocks

See Top Rated MarketRank™ Stocks Here
PRQR stock logo

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Analyst Ratings Changes

PRQR has been the topic of a number of research reports. Raymond James raised shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price target on the stock in a research note on Friday. HC Wainwright cut their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Cantor Fitzgerald lowered shares of ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday. StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Finally, Chardan Capital downgraded shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $5.00.

ProQR Therapeutics Stock Down 0.1 %

PRQR traded down $0.00 during trading on Tuesday, reaching $0.89. 10 shares of the stock were exchanged, compared to its average volume of 451,041. ProQR Therapeutics has a twelve month low of $0.53 and a twelve month high of $9.09. The stock's 50 day moving average price is $0.80 and its two-hundred day moving average price is $1.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93.

Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Stock News Headlines

August 16, 2022 | americanbankingnews.com
ProQR Therapeutics (NASDAQ:PRQR) Lowered to "Neutral" at Cantor Fitzgerald
August 16, 2022 | americanbankingnews.com
ProQR Therapeutics (NASDAQ:PRQR) Upgraded at Raymond James
August 16, 2022 | americanbankingnews.com
Raymond James Upgrades ProQR Therapeutics (NASDAQ:PRQR) to Outperform
August 14, 2022 | americanbankingnews.com
Chardan Capital Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Neutral
August 12, 2022 | finance.yahoo.com
Raymond James Bullish On This Penny Stock's Reprioritized Pipeline
August 12, 2022 | seekingalpha.com
ProQR upgraded at Raymond James on RNA-editing platform
August 12, 2022 | americanbankingnews.com
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $5.90
August 11, 2022 | finance.yahoo.com
This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing
August 11, 2022 | seekingalpha.com
ProQR says EU regulator seeks additional trial for lead candidate
August 11, 2022 | finance.yahoo.com
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
August 4, 2022 | finance.yahoo.com
ProQR Announces Second Quarter 2022 Operating and Financial Results
July 27, 2022 | americanbankingnews.com
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average of $0.76
July 8, 2022 | finance.yahoo.com
Investors in ProQR Therapeutics (NASDAQ:PRQR) have unfortunately lost 90% over the last three years
June 28, 2022 | finance.yahoo.com
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
June 1, 2022 | finance.yahoo.com
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
May 9, 2022 | finance.yahoo.com
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
May 6, 2022 | markets.businessinsider.com
Expert Ratings for ProQR Therapeutics
May 5, 2022 | finance.yahoo.com
ProQR (PRQR) Reports Q1 Loss, Tops Revenue Estimates
May 5, 2022 | finance.yahoo.com
ProQR Announces First Quarter 2022 Operating and Financial Results
May 3, 2022 | finance.yahoo.com
Bears are Losing Control Over ProQR (PRQR), Here's Why It's a 'Buy' Now
April 28, 2022 | finance.yahoo.com
ProQR (PRQR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
April 19, 2022 | finance.yahoo.com
ProQR to Participate in the Kempen Life Sciences Conference
April 13, 2022 | finance.yahoo.com
ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce
April 13, 2022 | msn.com
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022 | finance.yahoo.com
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings
11/04/2021
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
CUSIP
N/A
CIK
1612940
Web
www.proqr.com
Phone
(188) 166-7000
Fax
N/A
Employees
1,504
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+470.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-72,900,000.00
Net Margins
-1,859.05%
Pretax Margin
-1,866.41%
Return on Equity
-57.34%
Return on Assets
-31.84%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
5.93
Quick Ratio
5.93

Sales & Book Value

Annual Sales
$1.60 million
Price / Sales
39.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.88 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
71,290,000
Free Float
N/A
Market Cap
$62.45 million
Optionable
Optionable
Beta
0.80

Key Executives

  • Dr. Domenico Valerio Ph.D. (Age 66)
    Founder & Independent Chairman of Supervisory Board
    Comp: $71.38k
  • Mr. Daniel Anton de Boer (Age 39)
    Founder, CEO & Member of Management Board
    Comp: $757.63k
  • Ms. Theresa Marie Heggie (Age 62)
    Chief Operating Officer
    Comp: $29.57k
  • Dr. Gerard Platenburg (Age 58)
    Co-Founder & Chief Scientific Officer
  • Ms. Smital Shah M.B.A. (Age 46)
    Chief Bus. & Financial Officer
  • Mr. Rene K. Beukema (Age 58)
    Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board
  • Ms. Sarah Cue Kiely
    VP of Investor Relations & Corp. Communications
  • Ms. Sheila Sponselee
    VP of HR
  • Mr. Bart Klein
    Sr. VP of Intellectual Property
  • Mr. Aniz Girach M.D. (Age 55)
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.

What is ProQR Therapeutics' stock price forecast for 2022?

8 brokers have issued 1-year price targets for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.00 to $17.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 461.8% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2022?

ProQR Therapeutics' stock was trading at $8.01 on January 1st, 2022. Since then, PRQR shares have decreased by 88.9% and is now trading at $0.89.
View the best growth stocks for 2022 here.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PRQR earnings forecast.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.01. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $0.80 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 57.34% and a negative net margin of 1,859.05%.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Privium Fund Management B.V. (7.50%), Opaleye Management Inc. (3.84%), Prosight Management LP (2.40%), JPMorgan Chase & Co. (1.35%), Monaco Asset Management SAM (1.31%) and Renaissance Technologies LLC (1.30%).

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $0.89.

How much money does ProQR Therapeutics make?

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $63.45 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72,900,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

The company employs 1,504 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.